These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30412987)

  • 21. Combination of solifenacin and mirabegron for overactive bladder management.
    Cornu JN
    BJU Int; 2015 Oct; 116(4):498-9. PubMed ID: 26350574
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Vecchioli Scaldazza C; Morosetti C
    Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incontinence: Adding mirabegron to solifenacin improves patient outcomes.
    Sidaway P
    Nat Rev Urol; 2016 Jun; 13(6):298-9. PubMed ID: 27142125
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
    Morin F; Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
    J Urol; 2017 Apr; 197(4):1158-1163. PubMed ID: 27914999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
    Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
    Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.
    Weber MA; Chapple CR; Gratzke C; Herschorn S; Robinson D; Frankel JM; Ridder AM; Stoelzel M; Paireddy A; van Maanen R; White WB
    Blood Press Monit; 2018 Jun; 23(3):153-163. PubMed ID: 29578880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.
    West EG; McDermott C; Chess-Williams R; Sellers DJ
    Sci Rep; 2022 Jul; 12(1):12365. PubMed ID: 35858980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
    Drake MJ; MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Herschorn S; Huang M; Stoelzel M; Siddiqui E
    Urology; 2017 Jun; 104():1-4. PubMed ID: 28322904
    [No Abstract]   [Full Text] [Related]  

  • 30. Combined treatment with a β
    Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
    Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder.
    de Greef-van der Sandt I; Newgreen D; Schaddelee M; Dorrepaal C; Martina R; Ridder A; van Maanen R
    Clin Pharmacol Ther; 2016 Apr; 99(4):442-51. PubMed ID: 26422298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Therapy for Overactive Bladder: Who Approves?
    Staskin DR
    Eur Urol; 2018 Oct; 74(4):510-511. PubMed ID: 29933908
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.
    Wagg A; Nitti VW; Kelleher C; Castro-Diaz D; Siddiqui E; Berner T
    Curr Med Res Opin; 2016; 32(4):621-38. PubMed ID: 26828974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care].
    Kolbin AS; Vilyum IA; Proskurin MA; Balykina YE
    Urologiia; 2016 Feb; (1):32-39. PubMed ID: 28247701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
    Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T
    Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
    Nitti VW; Auerbach S; Martin N; Calhoun A; Lee M; Herschorn S
    J Urol; 2013 Apr; 189(4):1388-95. PubMed ID: 23079373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.
    Angulo JC; Khullar V; Nitti VW; Siddiqui E
    Actas Urol Esp; 2013; 37(10):640-51. PubMed ID: 23850394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
    Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
    Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Safety and Therapeutic Efficacy of Mirabegron 25 mg in Older Patients with Overactive Bladder and Multiple Comorbidities.
    Griebling TL
    J Urol; 2019 Mar; 201(3):421. PubMed ID: 30759633
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.